Clinical Trials
-
Principal Investigator
Prakash Satwani, MDThe main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma. -
Principal Investigator
Prakash Satwani, MDThe main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma. -
Principal Investigator
Alice Lee, MDThis is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with tumors, including CNS tumors. Both temozolomide and irinotecan are drugs that are FDA-approved for other indications. -
Principal Investigator
Stergios Zacharoulis, MDThe purpose of this study is to learn more about the treatment of children and young adults patient with relapsed (has returned) and progressive medulloblastoma (brain tumor). This study is being done to find out if bevacizumab can be safely given in combination with five study drugs given by mouth, thalidomide, fenofibrate, celecoxib and alternating every three weeks of etoposide and cyclophosphamide. -
Principal Investigator
Alice Lee, MDThe purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children with solid tumor which has come back or has not responded to the standard therapy. Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib will be given by mouth on Days 1-14 of a 21-day cycle. It will be given in combination with chemotherapy drugs Irinotecan and Temozolomide. -
We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy.
-
This is a Phase 3 multi-center open label randomized clinical trial. The purpose of this study is to learn more about which anti-rejection (or immunosuppressive) medications best protect infants, children, adolescents, and young adults after they have had a heart transplant. Two different drug regimens will be will be compared. All of these drugs are FDA-approved for adults, but not for children.
-
This is a Phase 3 multi-center open label randomized clinical trial. The purpose of this study is to learnmore about which anti-rejection (or immunosuppressive) medications best protect infants, children,adolescents, and young adults after they have had a heart transplant. Two different drug regimens will bewill be compared. All of these drugs are FDA-approved for adults, but not for children.
-
Principal Investigator
Alice Lee, MDThis is a Phase 1 multicenter study of pevonedistat in combination with Temozolomide and Irinotecan in pediatric patients with refractory solid tumors, including CNS tumors and lymphoma. The study treatment is considered experimental because pevonedistat is not approved by the United States (US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors and lymphoma.